Share

AdderaCare AB Stocks

SEK 0Last Updated 23.03.2026

Issuer Rating

Performance

Modest

Risk

Low

Recommendation

Sell

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0
Key Takeaways

Risk factor

Considerable default risk

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

AdderaCare AB, through its subsidiaries, operates in the assistive technology sector. The company provides disability ramps, including threshold, wheelchair, and access ramps; stairs and lifts; and bathroom equipment, such as toilets, showers, cabinets, mirrors, toilet armrests, and grab bars. It also offers sensory stimulation aids; sensory rooms; sensory furniture; vestibular products; motor activity products; orthopedic shoes; orthoses; orthotic aids; and prosthesis and components for prosthesis for children and adults with functional limitations, dementia, and mental disabilities. In addition, the company provides orthopedic aids; supervised cycling bikes; mobility scooters; and wheelchair scooters. It serves municipalities, county councils, and private individuals. The company was formerly known as Mastaban AB and changed its name to AdderaCare AB in 2016. AdderaCare AB was founded in 2013 and is based in Helsingborg, Sweden.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks